Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr

Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25

Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr

Q3 FY25 revenue up 24% to Rs 3,230 crore

Budget 2025: Industry expects tax incentives and thrust on affordable healthcare

Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials

Briefs: Cipla and IOL Chemicals and Pharmaceuticals

Mesalazine is used to treat inflammatory bowel disease

PM Modi lays foundation stone of Kris City and bulk Drug Park at Nakkapalli

The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs

Venus Remedies secures GMP certification for antibiotic carbapenem facility in Moldova

Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026

Zota Health Care receives licnese for Zotamet and Telmisartan in Kyrgyzstan

Aarti Drugs receives EIR from USFDA for Tarapur API facility

This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP

India is the fourth largest medical devices market in Asia: Anupriya Patel

The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities